

GLOBAL PRODUCT LIST H2'2023

| Product INN (Composition) | Dosage Form | Dosage Strength | Status | Dossier Type | Dossier Availability |
|---|--|---|--------|---------------|-------------------------------------|
| CONTRAST MEDIA | | | | | |
| MRI Contrast Media | | | | | |
| Gadoteric acid | Vial Sol. f/Inj. | 0.5 mmol/mL: 5 mL, 10 mL, 15 mL, 20 mL, 60 mL, 100 mL | Rx | EU CTD | Available |
| | PFS Sol. f/Inj. | 0.5 mmol/mL: 10 mL, 15 mL, 20 mL | | CTD | CTD - Available EU CTD - 4Q 2023 |
| Gadobutrol | Vial Sol. f/Inj. | 1.0 mmol/mL: 2 mL, 7.5 mL, 10 mL, 15 mL, 30 mL, 65 mL | Rx | EU CTD | Available |
| | PFS Sol. f/Inj. | 1.0 mmol/mL: 5 mL, 7.5 mL, 10 mL, 15 mL | | EU CTD | 4Q 2023 |
| X-RAY Contrast Media, Iodinated | | | | | |
| Iohexol | Vial Sol. f/Inj./Inf. | 350 mg iodine/mL: 20 mL, 50 mL, 100 mL, 200 mL, 500 mL 300 mg iodine/mL: 20 mL, 50 mL, 100 mL, 200 mL, 500 mL 240 mg iodine/mL: 50 mL, 100 mL | Rx | CTD EU CTD | CTD - Available EU CTD - 3Q 2023 |
| Amidotrizoate sodium | Amp. Sol. f/Inj. | 76%, 60%: 20 mL | Rx | CTD | Available |
| ANESTHETICS, NARCOTIC ANALGESICS | | | | | |
| Dexmedetomidine | Vial Sol. f/Inj. | 100 mcg/mL: 4 mL, 10 mL | Rx | EU CTD | Available |
| | Amp. Sol. f/Inj. | 100 mcg/mL: 2 mL | | CTD | Available |
| Fentanyl | Amp. Sol. f/Inj. | 0.05%: 2 mL | Rx | CTD | Available |
| Ketamine | Amp. Sol. f/Inj. | 50 mg/mL: 2 mL | Rx | CTD | Available |
| | Vial Sol. f/Inj. | 50 mg/mL: 10 mL | | CTD | Available |
| Nalbuphine | Amp. Sol. f/Inj. | 10 mg/mL: 1 mL, 2 mL | Rx | CTD | Available |
| | PFS Sol. f/Inj. | 10 mg/mL: 1 mL | | CTD | Available |
| Propofol | Vial Emuls. f/Inf. | 10 mg/mL: 20 mL, 50 mL, 100 mL 20 mg/mL: 20 mL, 50 mL, 100 mL | Rx | EU CTD | Available |
| | Amp. Emuls. f/Inf. | 10 mg/mL: 20 mL 20 mg/mL: 20 mL | | EU CTD | Available |
| Oxybate sodium | Amp. Sol. f/Inj. | 200 mg/mL: 5 mL, 10 mL | Rx | Local CTD | Available |
| Tramadol | Caps. solid | 50 mg | Rx | CTD | Available |
| | Amp. Sol. f/Inj. | 5%: 2 mL | | CTD | Available |
| SYSTEMIC HORMONAL PREPARATIONS | | | | | |
| Betamethasone dipropionate + Betamethasone sodium phosphate | Amp. Susp. f/Inj. | 7 mg/mL (5 mg + 2 mg): 1 mL | Rx | CTD | Available |
| | PFS Sol. f/Inj. | 7 mg/mL (5 mg + 2 mg): 1 mL | | CTD | Available |
| Betamethasone sodium phosphate | Amp. Sol. f/Inj. | 4 mg/mL: 1 mL | Rx | CTD | Available |
| Carbetocin | Vial Sol. f/Inj. | 100 mcg/mL: 1 mL | Rx | EU CTD | 2Q 2024 |
| | PFS Sol. f/Inj. | 100 mcg/mL: 1 mL | | EU CTD | 2Q 2024 |
| Desmopressin | Nasal drops | 0.1 mg/mL: 2.5 mL, 5 mL | Rx | CTD | Available |
| | MD Liquid, spray | 0.1 mg/mL: 2.5 mL, 5 mL | | CTD | Available |
| Dexamethasone | Amp. Sol. f/Inj. | 4 mg/mL: 1 mL, 2 mL | Rx | WHO CTD | Available |
| Hydrocortisone acetate | Amp. Susp. f/Inj. | 2.5%: 2 mL | Rx | CTD | Available |
| Levothyroxine sodium | Tablets | 25 mcg, 50 mcg, 75 mcg, 100 mcg, 125 mcg, 150 mcg | Rx | CTD EU CTD | CTD Available EU CTD - 4Q 2023 |
| Methylprednisolone | Tablets | 4 mg, 16 mg | Rx | EU CTD | 2Q 2025 |
| Octreotide | Amp. Sol. f/Inj. | 0.1 mg/mL: 1 mL | Rx | CTD | Available |
| Potassium iodide | Tablets | 100 mcg, 200 mcg | OTC | CTD | Available |
| Teripressin | Amp. Sol. f/Inj. | 0.12 mg/mL: 8.5 mL 0.2 mg/mL: 5 mL, 10 mL 0.1 mg/mL: 2 mL, 10 mL | Rx | EU CTD | 2Q 2024 |
| Vasopressin (Argipressin) | Amp. Sol. f/Inj. | 20 IU/mL: 1 mL, 2 mL | Rx | EU CTD | Available |
| ALIMENTARY TRACT AND METABOLISM | | | | | |
| Ademetionine | Enteric-coated tablets | 400 mg | Rx | CTD | Available |
| Antral | Film-coated tablets | 100 mg, 200 mg | OTC | CTD | Available |
| Benphothiaminum + Vitamin B6 | Film-coated tablets | 100 mg + 100 mg | OTC | CTD | Available |
| Domperidone | Film-coated tablets | 10 mg | OTC | CTD | Available |
| Fumaria officinalis + Silybum marianum | Caps. solid | 275.1 mg + 50 mg | OTC | CTD | Available |
| L-Ornithine L-Aspartate | Unit Dose Powd. Gran. f/oral Sol. Sachet | 3 g/5 g | OTC | CTD | Available |
| Macrogolum | Amp. Conc. f/Inf. Sol. | 500 mg/mL: 10 mL | Rx | CTD | Available |
| Mebeverine | Unit Dose Powd. f/oral Sol. Sachet | 64 g/73.69 g | Rx | CTD | Available |
| | Caps. solid (XR) | 200 mg | | CTD | Available |
| Mesalazine | Film-coated tablets | 135 mg | OTC | EU CTD | Available |
| | Tablets prolong. action (XR) | 1200 mg | | Rx | EU CTD |
| Omeprazole | Caps. solid | 10 mg, 20 mg, 40 mg | Rx | CTD | Available |
| Vitamin B1, B2, B6, Ascorbic Acid, Nicotinamide, Glucose | Amp. Sol. f/Inj. | 50 mg/mL: 5 mL | Rx | CTD | Available |
| Picorsulfate sodium | Drops oral Sol. | 0.75%: 15 mL, 25 mL, 30 mL | OTC | EU CTD | Available |
| Tablets | Tablets | 5 mg, 7.5 mg | OTC | EU CTD | Available |
| Vitamin B1, B6, B12 | Amp. Sol. f/Inj. | 50 mg/mL + 50 mg/mL + 0.5 mg/mL: 2 mL | Rx | EU CTD | Available |
| Vitamin B1, B2, B6, Ascorbic Acid, Nicotinamide, Glucose | Amp. Conc. f/Sol. f/Inf. | Amp. Vit. B1, B2, B6 + Amp. Vit. C, Nicotinamide, Glucose | Rx | EU CTD | Available |
| Diosmectite | Unit Dose Powd. f/oral Susp. Sachet | 3.76 g | OTC | CTD | Available |
| Ursodeoxycholic acid | Film-coated tablets | 250 mg, 500 mg | Rx | EU CTD | 2Q 2024 |
| Vonoprazan | Film-coated tablets | 10 mg, 20 mg | Rx | EU CTD | 3Q 2024 |

| Product INN (Composition) | Dosage Form | Dosage Strength | Status | Dossier Type | Dossier Availability |
|--|----------------------------------|--|---------|----------------|----------------------|
| DRUGS USED IN DIABETES | | | | | |
| Dapagliflozin | Film-coated tablets | 5 mg, 10 mg | Rx | EU CTD | 2Q 2024 |
| Dapagliflozin + Metformin | Film-coated tablets | 5 mg + 850 mg, 5 mg + 1000 mg | Rx | EU CTD | 4Q 2024 |
| Empagliflozin | Film-coated tablets | 10 mg, 25 mg | Rx | EU CTD | 3Q 2025 |
| Empagliflozin + Metformin | Film-coated tablets | 12.5 mg + 850 mg, 12.5 mg + 1000 mg | Rx | EU CTD | 2Q 2026 |
| Glucalazine | Tablets | 80 mg | Rx | CTD | Available |
| | Tablets modified release (MR) | 30 mg, 60 mg | | | |
| Glimepiride | Tablets | 2 mg, 3 mg, 4 mg | Rx | CTD | Available |
| | Film-coated tablets | 500 mg, 850 mg, 1000 mg | | | |
| Metformin | Tablets prolong. action (XR) | 500 mg, 750 mg, 1000 mg | Rx | EU CTD | Available |
| | Caps. solid | 300 mg | | CTD | |
| | Amp. Conc. f/Inf. Sol. | 3%: 10 mL, 20 mL | | CTD | |
| Thioctic acid | Vial Sol. f/Inf. | 1.2%: 50 mL | Rx | CTD | Available |
| | Film-coated tablets (HR) | 600 mg | | EU CTD | |
| | Film-coated tablets | 50 mg, 100 mg | | Rx | |
| Sitagliptin | Film-coated tablets | 50 mg, 100 mg | Rx | EU CTD | Available |
| Sitagliptin + Metformin | Film-coated tablets | 50 mg + 850 mg, 50 mg + 1000 mg | Rx | EU CTD | Available |
| BLOOD AND BLOOD FORMING ORGANS | | | | | |
| Acetylsalicylic acid | Film-coated tablets | 75 mg, 150 mg | OTC | CTD | Available |
| Clopidogrel | Film-coated tablets | 75 mg | Rx | CTD | Available |
| Enoxaparin | PFS Sol. f/Inj. | 2000 anti-Xa IU: 0.2 mL 4000 anti-Xa IU: 0.4 mL 6000 anti-Xa IU: 0.6 mL 8000 anti-Xa IU: 0.8 mL | Rx | CTD | Available |
| | Vial Sol. f/Inj. | 30 000 anti-Xa IU: 3 mL | | | |
| Ferric carboxymaltose | Vial Sol. f/Inj. | 50 mg iron/mL: 2 mL, 10 mL, 20 mL | Rx | EU CTD | 2Q 2025 |
| Fondaparinux | PFS Sol. f/Inj. | 2.5 mg/0.5 mL: 0.5 mL | Rx | CTD | Available |
| Tranexamic acid | Film-coated tablets | 500 mg | Rx | CTD | Available |
| | Amp. Sol. f/Inj. | 50 mg/mL: 5 mL, 10 mL 100 mg/mL: 5 mL, 10 mL | | EU CTD | |
| CARDIOVASCULAR SYSTEM | | | | | |
| Amlodipine | Tablets | 5 mg, 10 mg | Rx | CTD | Available |
| Apixaban | Film-coated tablets | 2.5 mg, 5 mg | Rx | EU CTD | Available |
| L-arginine aspartate | Liquid oral Sol. | 200 mg/mL: 100 mL, 200 mL | OTC, FS | CTD, Tech File | Available |
| Atorvastatin | Film-coated tablets | 10 mg, 20 mg, 40 mg, 80 mg | Rx | CTD | Available |
| Bisoprolol | Tablets | 2.5 mg, 5 mg, 10 mg | Rx | CTD | Available |
| Diosmin + Hesperedin | Film-coated tablets | 500 mg | OTC | CTD | Available |
| Enalapril | Tablets | 5 mg, 10 mg | Rx | CTD | Available |
| Enalapril + Hydrochlorothiazide | Tablets | 20 mg + 12.5 mg, 10 mg + 25 mg, 10 mg + 12.5 mg | Rx | CTD | Available |
| Levosimendan | Vial Conc. f/Inf. Sol. | 2.5 mg/mL: 5 mL | Rx | EU CTD | Available |
| Lercanidipine | Tablets | 10 mg, 20 mg | Rx | EU CTD | Available |
| Meldonium | Caps. solid | 250 mg, 500 mg | Rx | CTD | Available |
| | Amp. Sol. f/Inj. | 100 mg/mL: 5 mL | | | |
| Nifedipine | Drops oral Sol. | 2%: 5 mL, 25 mL | Rx | CTD | Available |
| Ramipril | Tablets | 2.5 mg, 5 mg, 10 mg | Rx | CTD | Available |
| Ramipril + Hydrochlorothiazide | Tablets | 2.5 mg + 12.5 mg | Rx | CTD | Available |
| | | 5 mg + 12.5 mg, 5 mg + 25 mg 10 mg + 12.5 mg, 10 mg + 25 mg | | | |
| Ranolazine | Tablets prolong. action (XR) | 375 mg, 500 mg, 750 mg, 1000 mg | Rx | EU CTD | Available |
| Rivaroxaban | Film-coated tablets | 10 mg, 15 mg, 20 mg | Rx | EU CTD | Available |
| Torasemide | Tablets | 5 mg, 10 mg | Rx | CTD | Available |
| Amp. Sol. f/Inj. | 5 mg/mL: 2 mL, 4 mL | | | | |
| Ticagrelor | Film-coated tablets | 60 mg, 90 mg | Rx | EU CTD | Available |
| Valsartan + Amlodipine | Film-coated tablets | 5 mg + 80 mg, 5 mg + 160 mg, 10 mg + 160 mg | Rx | CTD | Available |
| Valsartan + Sacubitril | Film-coated tablets | 50 mg, 100 mg, 200 mg | Rx | EU CTD | 2Q 2024 |
| HOSPITAL SOLUTIONS | | | | | |
| L-arginine hydrochloride | Vial Sol. f/Inf. | 42 mg/mL: 100 mL | Rx | CTD | Available |
| Asparginat K-Mg | Amp. Sol. f/Inj. | 5 mL, 10 mL, 20 mL | Rx | CTD | Available |
| Calcium gluconate | Amp. Sol. f/Inj. | 100 mg/mL: 5 mL, 10 mL | Rx | EU CTD | Available |
| Dextrose | Amp. Sol. f/Inj. | 40%: 10 mL, 20 mL | Rx | CTD | Available |
| DERMATOLOGICAL | | | | | |
| Aciclovir | Cream | 5%: 5 g | OTC | CTD | Available |
| Aciclovir (with menthol flavor) | Cream | 5% + 1%: 5 g | OTC | CTD | Available |
| Dimetindene | Gel | 0.1%: 30 g | OTC | CTD | Available |
| Mometasone | Cream | 0.1%: 15 g | Rx | CTD | Available |
| | Ointment | 0.1%: 15 g | | | |
| Mometasone + Salicylic acid | Ointment | 1 mg/g + 50 mg/g: 15 g | Rx | CTD | Available |
| | Cream | 1%: 15 g | | | |
| Naftifine | Cutaneous Sol. | 1%: 15 mL, 20 mL, 25 mL | OTC | CTD | Available |
| | Cutaneous spray | 1%: 15 mL, 25 mL | | | |
| Octenidine + Phenoxethanol | Topical Sol. | 200 mL, 500 mL | OTC | EU CTD | 2Q 2024 |
| | Cutaneous spray | 30mL, 50mL with vaginal applicator | | | |
| Terbinafine | Cream | 1%: 15 g | OTC | CTD | Available |
| | Gel | 1%: 15 g, 30 g | | | |
| Cutaneous spray | Cutaneous spray | 1%: 25 g | | | |
| ANTIINFECTIVES FOR SYSTEMIC USE | | | | | |
| Aciclovir | Tablets | 200 mg, 400 mg, 800 mg | Rx | EU CTD | Available |
| Dioxidine | Amp. Sterile Sol. | 10 mg/mL: 10 mL | Rx | CTD | Available |
| | Caps. solid | 500 mg | | | |
| Enisamium iodide | Film-coated tablets | 125 mg, 250 mg | OTC | Original | Available |
| | Syrup | 10 mg/mL: 100 mL | | | |
| Inosine pranobex | Syrup | 90 mg/mL: 100 mL 100 mg/mL: 100 mL | Rx | CTD | Available |
| | Tablets | 500 mg | | | |
| Itraconazole | Caps. solid | 100 mg | Rx | CTD | Available |
| Moxifloxacin | Vial sol. f/inf. | 400 mg/250 mL | Rx | EU CTD | 3Q 2023 |
| Terbinafine | Tablets | 250 mg | Rx | CTD | Available |
| Valaciclovir | Film-coated tablets | 500 mg | Rx | CTD | Available |
| GENITOURINARY SYSTEM AND SEX HORMONES | | | | | |
| Hydrogestrone | Tablets | 10 mg | Rx | EU CTD | 1Q 2025 |
| Hydroxyprogesterone capros | Amp. Sol. f/Inj. in ethyl oleate | 12.5%: 1 mL | Rx | CTD | Available |
| Progesterone | Amp. Sol. f/Inj. in ethyl oleate | 1.0%, 2.5%: 1 mL | Rx | CTD | Available |
| | Caps. soft oral, vaginal | 100 mg, 200 mg | | EU CTD | |
| Testosterone undecanoate | Vial Sol. f/Inj. | 250 mg/mL: 4 mL | Rx | EU CTD | 3Q 2025 |

| Product INN (Composition) | Dosage Form | Dosage Strength | Status | Dossier Type | Dossier Availability |
|--|-------------------------------------|--|---------|----------------|----------------------|
| Testosterone propionate | Amp. Sol. f/Inj. in ethyl oleate | 5%: 1 mL | Rx | CTD | Available |
| Phytoextract: Allium Cera L. + Rhiroma Agropyri + Betaulae folium + Foenugraeci semen + Radix Petroselinii + Solidaginifera herba + Equiseti herba + Polygoni avicularis herba + Radix Levistici | Drops oral Sol. | 25 mL, 50 mL | OTC | Local CTD | Available |
| | Film-coated tablets | 188 mg phytoextracts from 9 plants | | | |
| | Gel | 100 g | | | |
| | Syrup | 100 mL | | | |
| IMMUNOMODULATING AGENTS | | | | | |
| Interferon alfa-2b | Nasal drops | 100000 IU/mL: 5 mL | OTC | CTD | Available |
| | Nasal spray | 100000 IU/mL: 5 mL | | | |
| MUSCULO-SKELETAL SYSTEM | | | | | |
| Atracturium | Amp. Sol. f/Inj. | 10 mg/mL: 2.5 mL, 5 mL | Rx | EU CTD | 3Q 2023 |
| | Ointment | tube 30 g | OTC | CTD | Available |
| Chondroitin sulfate + Levomenthol | Unit Dose Powd. f/oral Sol. Sachet | 1.5 g | Rx | CTD | Available |
| Glucosamine sulphate | Amp. Sol. f/Inj. | 200 mg/mL: 2 mL + solvent in Amp. 1 mL | OTC/Rx | EU CTD | 3Q 2023 |
| | Tablets | 200 mg, 400 mg, 600 mg | | | |
| Ibuprofen | Gel | 2.5% tube 30 g | Rx | CTD | Available |
| Ketoprofen | Amp. Sol. f/Inj. | 30 mg/mL: 1 mL | Rx | CTD | Available |
| | Film-coated tablets | 10 mg | | | |
| Ketorolac | Amp. Sol. f/Inj. | 1%: 1.5 mL | Rx | EU CTD | Available |
| | Tablets | 7.5 mg, 15 mg | | EU CTD | |
| | Rectal Suppository | 15 mg | | CTD | |
| Meloxicam | Unit Dose Powd. f/oral Susp. Sachet | 100 mg | Rx | CTD | Available |
| Nimesulide | Film-coated tablets | 50 mg, 150 mg | Rx | CTD | Available |
| | Amp. Sol. f/Inj. | 100 mg/mL: 1 mL | | | |
| Tolperisone | Amp. Sol. f/Inj. | 100 mg/mL: 1 mL | Rx | CTD | Available |
| NERVOUS SYSTEM | | | | | |
| Betahistine | Tablets | 8 mg, 16 mg, 24 mg | Rx | CTD | Available |
| | Caps. soft | 400 mg | | | |
| Choline alfoscerate | Amp. Sol. f/Inj. | 250 mg/mL: 4 mL | Rx | CTD | Available |
| | Vial oral Sol. | 600 mg: 7 mL | | | |
| | Film-coated tablets | 500 mg | | | |
| Citicoline | Liquid oral Sol. | 100 mg/mL: 30 mL, 60 mL | Rx | CTD | Available |
| | Amp. Sol. f/Inj. | 900 mg/4 mL: 4 mL 1000 mg/4 mL: 4 mL | | | |
| Dexketoprofen | Film-coated tablets | 25 mg | Rx | CTD | Available |
| | Amp. Sol. f/Inj. | 50 mg/2 mL: 2 mL | | CTD | |
| | Unit Dose Gran. f/oral Sol. Sachet | 25 mg | | EU CTD | |
| Edaravone | Amp. Sol. f/Inj. | 1.5 mg/mL: 20 mL | Rx | ICH | Available |
| Gabapentin | Vial Sol. f/Inj. | 0.3 mg/mL: 100 mL | Rx | CTD | Available |
| Lamotrigine | Caps. solid | 300 mg | Rx | CTD | Available |
| Lamotrigine | Tablets | 50 mg; 25 mg; 100 mg | Rx | CTD | Available |
| | Amp. Sol. f/Inj. | 10 mg/mL: 2 mL | | | |
| Nefopam | Film-coated tablets | 30 mg | Rx | EU CTD | Available |
| Olanzapine | Film-coated tablets | 2.5 mg, 5 mg, 10 mg | Rx | ICH | 3Q 2023 |
| Paliperidone | PFS prolonged-release Susp. f/Inj. | 100 mg/mL: 0.5 mL, 0.75 mL, 1 mL, 1.5 mL | Rx | EU CTD | 3Q 2026 |
| Paracetamol | Vial Sol. f/Inf. | 10 mg/mL: 100 mL | Rx | CTD | Available |
| Piracetam | Caps. solid | 400 mg | OTC | CTD | Available |
| | Amp. Sol. f/Inj. | 20%: 5 mL, 10 mL, 20 mL | | | |
| Piracetam + Cinnarizine | Caps. solid | 400 mg + 25 mg | Rx | CTD | Available |
| Pregabalin | Caps. solid | 75 mg, 150 mg, 300 mg | Rx | CTD | Available |
| Zolmitriptan | Film-coated tablets | 2.5 mg | Rx | CTD | Available |
| | Nasal spray | 2.5 mg/dose, 5 mg/dose: 2 mL | | | |
| OTC Brand, Combination and Herbal Drugs | | | | | |
| Acetylsalicylic acid + Paracetamol + Caffeine | Tablets | 300 mg + 100 mg + 50 mg | OTC | CTD | Available |
| Valeriana + Melissa + Passiflorae | Tablets | 250 mg + 250 mg + 65 mg | OTC | EU CTD | 4Q 2023 |
| | Film-coated tablets | 125 mg + 112.5 mg + 80 mg | | CTD | Available |
| Guaifenesin + Crataegi folium + Lupuli flos + Hyperici herba + Melissa + Passiflorae + Sambuci flos + Valerianae | Liquid oral Sol. | Guaifenesin 40 mg + phytoextracts from 8 plants: 100 mL | OTC | CTD | Available |
| Doxylamine + Ethyl -bromo-isovaleric acid + Menthyl isovalerate (Local Brand - Sonobarboval) | Drops oral Sol. | 18 mg/mL + 80 mg/mL + 16.875 mg/mL: 5 mL | OTC | CTD | Available |
| Ethyl -bromo-isovaleric acid + Menthyl isovalerate + Mint oil + Hsp oil (Local Brand - Corvalol N/A) | Caps. soft | 16.62 mg + 45.74 mg + 0.17 mg + 1.18 mg | OTC | CTD | Available |
| | Drops oral Sol. | 20 mg/mL + 55 mg/mL + 1.42 mg/mL + 0.2 mg/mL: 25 mL | | | |
| Menthyl isovalerate (Brand - Validol) | Sublingual tablets | 60 mg | OTC, FS | CTD, Tech File | Available |
| RESPIRATORY SYSTEM | | | | | |
| Asthma, COPD | | | | | |
| Budesonide | Unit Dose Susp. f/Inhalation | 0.125 mg/mL: 2 mL 0.25 mg/mL: 2 mL 0.5 mg/mL: 2 mL | Rx | EU CTD | Available |
| Erdosteine | Caps. solid | 300 mg | Rx | EU CTD | 4Q 2024 |
| Fenoterol hydrobromide + Ipratropium bromide | Sol. f/Inhalation | 0.5 mg/mL + 0.25 mg/mL: 20 mL, 25 mL | Rx | EU CTD | Available |
| | Unit Dose Sol. f/Inhalation | 0.5 mg/4 mL + 1.25 mg/4 mL: 4 mL | | | 3Q 2023 |
| Ipratropium bromide | Liquid f/Inhalation | 0.25 mg/mL: 25 mL | Rx | CTD | Available |
| Theophylline | Amp. Sol. f/Inj. | 2%: 5 mL, 10 mL | Rx | CTD | Available |
| Oral sprays, Nasal sprays | | | | | |
| Benzydamine | Oromucosal Sol. | 1.5 mg/mL: 100 mL, 300 mL | OTC | EU CTD | Available |
| | Spray f/mouth cavity | 1.5 mg/mL: 15 mL, 30 mL | | | |
| | Spray f/mouth cavity | 3 mg/mL: 15 mL, 30 mL | | | |
| Benzydamine + Cetylpyridinium chloride | Spray f/mouth cavity | 1.5 mg/mL + 5 mg/mL: 30 mL | OTC | EU CTD | Available |
| | Flurbiprofen | Spray f/mouth cavity | | | |
| Hexetidine + Choline salicylate + Chlorbutanol hemihydrate | Liquid Sol. f/mouth | 1 mg/mL + 5 mg/mL + 2.5 mg/mL: 100 mL | OTC | CTD | Available |
| | Spray f/mouth cavity | 1 mg/mL + 5 mg/mL + 2.5 mg/mL: 20 mL, 50 mL | | | |
| Naphazoline | Nasal drops | 0.1%: 10 mL, 0.05%: 10 mL | OTC | CTD | Available |
| | Nasal drops | 0.5 mg/mL: 15 mL, 10 mL 0.25 mg/mL: 10 mL 0.1 mg/mL: 10 mL | | | |
| Oxymetazoline | Nasal Spray | 0.5 mg/mL: 15 mL | OTC | EU CTD | Available |
| Oxymetazoline with Eucalyptus and Chamomile | Nasal Spray | 0.5 mg/mL: 10 mL | OTC | EU CTD | Available |
| Oxymetazoline with Levomenthol | Nasal Spray | 0.5 mg/mL: 10 mL | OTC | EU CTD | Available |
| Phenylephrine + Dimethindene maleate | Nasal drops | 2.5 mg/mL + 0.25 mg/mL: 10 mL | OTC | CTD | Available |
| | Nasal Spray | 2.5 mg/mL + 0.25 mg/mL: 10 mL | | | |
| Xylometazoline | Nasal drops | 0.1%: 10 mL 0.05%: 10 mL | OTC | CTD | Available |
| | Nasal Spray | 1 mg/mL: 15 mL | | | |
| Xylometazoline with Mint oil | Nasal Spray | 1 mg/mL: 10 mL | OTC | CTD | Available |
| Xylometazoline with oil of Eucalyptus | Nasal Spray | 1mg/g: 10g | OTC | CTD | Available |



A THRIVING INTERNATIONAL PHARMACEUTICAL COMPANY FOCUSED ON SPECIALTY GENERICS

| Product INN (Composition) | Dosage Form | Dosage Strength | Status | Dossier Type | Dossier Availability |
|---|---|--|---------|----------------|----------------------|
| Cough & Cold | | | | | |
| Acetylcysteine | Unit Dose Powd. f/oral Sol. Sachet | 100 mg, 200 mg, 600 mg | OTC | CTD | Available |
| Ambroxol | Syrup | 30 mg/5 mL, 15 mg/5 mL; 100 mL | OTC | CTD | Available |
| Ambroxol + Carbocisteine | Syrup | 15 mg/5 mL + 100 mg/5 mL; 100 mL | OTC | CTD | Available |
| Butamirate citrate + Guaiphenesin | Drops oral Sol. | 4 mg/mL + 100 mg/mL; 25 mL | OTC | CTD | Available |
| Dry Ivy leaf extract (Hedera helix) | Syrup | 100 mL | OTC | EU CTD | Available |
| | Caps. soft | 52.5 mg | OTC, FS | CTD, Tech File | Available |
| Lysozyme hydrochloride + Dequalinium chloride | Losenges tablets 10mg + 0.25mg with taste | taste of orange taste of chocolate taste of raspberry taste of anise and mint | OTC | CTD | Available |
| Paracetamol + Phenylephrine | Unit Dose Powd. f/oral Sol. Sachet | 650 mg + 10 mg with taste of black currant with taste of lemon | OTC | CTD | Available |
| Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid | Unit Dose Powd. f/oral Sol. Sachet | 325 mg + 10 mg + 20 mg + 50 mg | OTC | CTD | Available |
| | Drops oral Sol. | 800 mg/g; 20 mL, 25 mL, 50 mL | | | |
| Pelargonium sidosides | Enteric-coated tablets | 20 mg | OTC | CTD | Available |
| | Syrup | 800 mg/g; 100 mL | | | |
| Antihistamines, Antiallergic | | | | | |
| Desloratadine | Film-coated tablets | 5 mg | OTC | CTD | Available |
| | Syrup | 0.5 mg/mL; 60 mL, 100 mL | | | |
| Dimetindene | Drops oral Sol. | 1.0 mg/mL; 25 mL, 20 mL | OTC | CTD | Available |
| Cromoglicic acid | Nasal Spray | 2%; 15 mL | OTC | CTD | Available |
| Mebhydrolin | Dragee | 50 mg, 100 mg | OTC | CTD | Available |
| | Tablets | 50 mg, 100 mg | | | |
| Rupatadine | Oral Sol. | 1 mg/mL; 100 mL | Rx | EU CTD | Available |
| SENSORY ORGANS | | | | | |
| Ophthalmology | | | | | |
| Betaxolol | Eye drops suspension | 2.5 mg/mL; 5 mL | Rx | CTD | Available |
| Brimonidamide | Eye drops suspension | 10 mg/mL; 5 mL | Rx | CTD | Available |
| Brimonidine | Eye drops Sol. | 2 mg/mL; 5 mL | Rx | CTD | Available |
| Brimonidine + Brinzolamide | Eye drops suspension | 2 mg/mL + 10 mg/mL; 5 mL | Rx | EU CTD | 1Q 2025 |
| Brimonidamide + Timolol | Eye drops Sol. | 10 mg/mL + 5 mg/mL; 5 mL | Rx | CTD | Available |
| Brimonidine + Timolol | Eye drops Sol. | 2 mg/mL + 5 mg/mL; 5 mL | Rx | EU CTD | Available |
| Cromoglicic acid | Eye drops Sol. | 2%; 10 mL | Rx | CTD | Available |
| Dexamethasone | Eye drops Sol. | 1 mg/mL; 5 mL, 10 mL | Rx | CTD | Available |
| Diclofenac | Eye drops Sol. | 0.1%; 5 mL, 10 mL | Rx | CTD | Available |
| Latanoprost | Eye drops Sol. | 0.05 mg/mL; 2.5 mL | Rx | EU CTD | Available |
| Latanoprost + Timolol | Eye drops Sol. | 0.05 mg/mL + 5 mg/mL; 2.5 mL | Rx | EU CTD | Available |
| Moxifloxacin | Eye drops Sol. | 0.5%; 5 mL | Rx | EU CTD | Available |
| Pilocarpine | Eye drops Sol. | 10 mg/mL; 5 mL, 10 mL | Rx | CTD | Available |
| Sulfacetamide | Eye drops Sol. | 300 mg/mL; 5 mL, 10 mL; 200 mg/mL; 5 mL, 10 mL | Rx | CTD | Available |
| Taurine | Eye drops Sol. | 40 mg/mL; 5 mL, 10 mL | Rx | CTD | Available |
| Tetrazoline | Eye drops Sol. | 0.5 mg/mL; 10 mL | OTC | CTD | Available |
| Timolol | Eye drops Sol. | 2.5 mg/mL; 5 mL, 10 mL; 5 mg/mL; 5 mL, 10 mL | Rx | CTD | Available |
| Travoprost | Eye drops Sol. | 0.04 mg/mL; 2.5 mL | Rx | CTD | Available |
| Tropicamide | Eye drops Sol. | 0.5%; 5 mL, 10 mL; 1%; 5 mL, 10 mL | Rx | CTD | Available |
| Eye / Ear | | | | | |
| Ciprofloxacin | Drops f/eye / ear | 0.3%; 5 mL, 10 mL | Rx | CTD | Available |
| Ciprofloxacin + Dexamethasone | Ear drops suspension | 3.5 mg/mL + 1 mg/mL; 7.5 mL | Rx | CTD | Available |
| | Eye drops suspension | 3.5 mg/mL + 1 mg/mL; 7.5 mL | | | |
| Phenazone + Lidocaine | Ear drops Sol. | 16 g | OTC | CTD | Available |
| ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | | | | | |
| Cyproterone | Tablets | 50 mg, 100 mg | Rx | CTD | Available |
| | Amp. Sol. f/Inj. in oil | 100 mg/mL; 3 mL | | | |
| Flutamide | Tablets | 125 mg, 250 mg | Rx | CTD | Available |
| Letrozole | Film-coated tablets | 2.5 mg | Rx | CTD | Available |
| API | | | | | |
| | Therapeutic class | CAS | DMF | WC | CEP |
| ACTIVE PHARMACEUTICAL INGREDIENTS | | | | | |
| Dimetindene maleate | Respiratory system Dermatologicals | 3614-69-5 | EU | + | in process |
| Methisoprinole (Inosine pranobex) | Antinfectives f/systemic use | 36703-88-5 | EU | + | - |

GLOBAL EXPORT NETWORK COVERS 25% OF THE WORLD'S COUNTRIES

Farmak AG

Lindenstrasse 4
CH-6340 Baar ZG
Switzerland
www.farmak.ch

E-mail: bd@farmak.ch



The information provided is the exclusive property of Farmak AG and is intended solely for demonstration and acquaintance of business partners of the Farmak AG. Any distribution, copying, duplication or other transfer of this information to any third parties, public display or disclosure of the information in any other way, any use of this information for other purposes, processing, adaptation or other similar change of this information is prohibited as well as any other actions that may lead to access to this information by other persons.